US20210346296A1 - A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same - Google Patents

Abstract

The present application provides a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component, in which a biologically active substance is uniformly dispersed, wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present in the microsphere. The microsphere of the present invention can appropriately control the initial release amount of the biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time.

Description

TECHNICAL FIELD
• The present inventions relate to a microsphere in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same. The present inventions specifically relate to a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component in which a biologically active substance is uniformly dispersed and a sustained release formulation comprising the same.
BACKGROUND ART
• Recently, a microsphere or nanosphere has attracted attention as a sustained release formulation of a medicine containing a biologically active substance or the like. A microsphere generally refers to a formulation having a particle diameter of 1 μm to about 150 μm, and a formulation smaller than that having a particle diameter less than 1 μm is referred to as a nanosphere. For example, when a biologically active substance is incorporated in a biodegradable synthetic or natural polymer, the biologically active substance can be continuously released locally, or the biologically active substance can be targeted to a tissue.
• A sustained release microsphere formulation which gradually releases a biologically active substance at a constant rate, needs to be, for example, a formulation in which a biodegradable polymer, a biologically active substance, an additive, a solvent and the like are appropriately controlled. In order for a sustained release microsphere formulation to effectively exhibit a pharmacological effect in vivo for a predetermined period of time, it is necessary to continuously release the biologically active substance in vivo for a predetermined period of time, by appropriately controlling the initial release amount of the biologically active substance and its release rate during a subsequent release period.
• One of the important factors for determining the release rate of the biologically active substance is a kind of biodegradable polymers. Particularly, the most widely used lactic acid-glycolic acid copolymer (polylactide-co-glycolide acid, PLGA) has a different biodegradation rate depending on its physicochemical properties such as a ratio of lactic acid and glycolic acid, its molecular weight, its affinity with water and the like, and thus, the biodegradation rate can be adjusted to a desired release period (Patent Literature 1).
• Furthermore, in addition to that, a particle diameter of the microsphere and a dispersion state of the biologically active substance in the microsphere are related, in order to suppress an abnormal initial release amount (an initial burst) of a biologically active substance and to control its release rate during a release period to be constant. In spite of a problem of yield, the particle diameter of the microsphere can be adjusted to a desired particle diameter by an operation such as filtration. However, the dispersion state of the biologically active substance in the microsphere has been reported only as uniform, and has not been confirmed.
• A microsphere of PLGA can be produced using, for example, a method of drying in liquid, a spray drying method, a spray freeze drying method, a drying method using a supercritical fluid process, a double emulsification method, or the like. When a biologically active substance is lipophilic, the most common production method among these methods is a method of drying in liquid in which PLGA and the biologically active substance are dissolved or dispersed in an organic solvent, mixed and emulsified with an aqueous solution in which polyvinyl alcohol (PVA) is dissolved, and the solvent is removed from the emulsion.
• Patent Literature 1 discloses a method of producing a sustained release microsphere containing a biodegradable polymer such as PLGA and a peptide medicine by a spray drying method, a spray freeze drying method or a drying method using a supercritical fluid process. However, Patent Literature 1 does not describe how much the particle diameter of the sustained release microsphere varies, whether or not the peptide medicine is uniformly dispersed in the sustained release the microsphere, and whether a uniformly dispersed microsphere is obtained.
• Patent Literature 2 discloses a method of producing PLGA microparticles by a method of drying in liquid using a mixed solvent comprising a halogenated hydrocarbon and a water-immiscible organic solvent having a solubility of a medicine of 0.3% (W/V) or more.Patent Literature 2 describes that particle diameters (median diameters) of the microparticles obtained in Production Examples 1 and 2 are respectively 14 and 16 but does not describe the dispersion state of the medicine in the microparticles.
• Patent Literature 3 discloses PLGA nanoparticles containing a biologically active substance. These nanoparticles are mainly intended for targeting to a specific tissue, and are nanoparticles of several tens nm to several hundreds nm which can pass through microscopic pores of blood capillaries. However, Patent Literature 3 does not describe a microsphere of 1 μm or more much larger than these nanoparticles. Even with the technique of Patent Literature 3, a person skilled in the art could not produce a microsphere having a particle diameter of 1 μm or more.
• Patent Literature 4 discloses a formulation which releases leuprorelin acetate of a luteinizing hormone releasing hormone derivative, during from about 1 month to several months by subcutaneous injection. The formulation has a problem that a distribution of the particle diameters is very wide from 1 μm to 400 Therefore,Patent Literature 5 proposes as a method for solving this problem, a method of producing a microsphere in which a biologically active substance is encapsulated in a polymer for a carrier by a double emulsification method. However,Patent Literature 5 does not describe the dispersion state of the medicine in the leuprorelin acetate containing the microspheres obtained in Examples 1 to 5.
• Patent Literature 6 discloses a microsphere which reduces a chronic pain for at least 28 days (672 hours). The microsphere comprises a biodegradable polymer and a local anesthetic (a biologically active substance), and releases about 75% of the local anesthetic during about 72 hours, and about 80 to 90% of the local anesthetic during about 120 hours. This suggests that the distribution of the local anesthetic in the microsphere is not uniform in the microsphere, and is biased in the outer side. From the SEM (scanning electron microscope) image of a cross section of the microsphere described inFIG. 2, the dispersion state of the local anesthetic cannot be determined, and the local anesthetic or an empty hole of 1.5 μm or more is confirmed.
• Patent Literature 7 discloses a core shell structure microsphere in which a core contains solid aripiprazole, and the surface of the core is coated with a shell containing a biodegradable polymer. As described above, the microsphere of Patent Literature 7 is not a microsphere in which the biologically active substance is uniformly dispersed. Further, in the electron microscope photograph of a cross section obtained by cutting the microsphere obtained in the example shown inFIG. 5, empty holes larger than 1.5 μm are confirmed.
CITATION LISTPatent Literature
• Patent Literature 1: JP 2005-035994
• Patent Literature 2: JP 2005-015476
• Patent Literature 3: JP 4856752
• Patent Literature 4: JP 2653255
• Patent Literature 5: JP 2014-224114
• Patent Literature 6: JP 2016-069378
• Patent Literature 7: JP 2010-531303
SUMMARY OF THE INVENTIONTechnical Problem
• A biodegradable polymer microsphere having an average volume-based particle diameter of 1 μm or more and 150 μm or less cannot be put in practice as its release period is designed, unless the distribution of a biologically active substance and the empty holes in the microsphere are controlled. For example, when the biologically active substance is biased near the surface of the microsphere, a large amount of the biologically active substance is released from the microsphere at the initial period after administration to generate the problem of the initial burst. On the other hand, when the biologically active substance is biased in the center of the microsphere or when the microsphere is in a state of a core shell structure, the biologically active substance cannot be released continuously from the initial period. A state in which the biologically active substance is uniformly dispersed in the microparticle, is desirable. When it is in a dispersed state in which large masses of the biologically active substance are scattered, the biologically active substance cannot be released continuously from the initial period. Similarly, when empty holes are not controlled, a similar problem occurs in the release of the biologically active substance.
• The uniform dispersion of the biologically active substance in the microsphere is the absolute condition for continuously releasing the biologically active substance in vivo for a predetermined period of time. Since the particle diameter of the microsphere is large unlike that of the nanoparticle, homogenization of the microsphere is generally difficult. Therefore, it is necessary to confirm the dispersion state of the biologically active substance in the microsphere.
• FIG. 1 is a microphotograph of the microcapsule sustained release formulation leuplin (registered trademark) for injection 1.88 mg (Takeda Pharmaceutical Company Limited), which corresponds to the sustained release microcapsule of a LH-RH derivative described in Patent Literature 4. The formulation includes various sizes of particles from large particles to small particles.FIG. 2 is an SEM (scanning electron microscope) image of a cross section of the particle of about 35 μm which was selected as a representative particle. When compared withFIG. 3 which is an SEM image of the PLGA microparticle without the biologically active substance of Reference Example 1, masses of the dispersed biologically active substance and empty holes are confirmed inFIG. 2, and many masses of the biologically active substance and many empty holes of 2 μm or more are confirmed. Whether it is a biologically active substance or an empty hole is confirmed by performing elemental analysis using an EDS (energy dispersive X-ray spectrometer). The microsphere in such state in which the biologically active substance is not uniformly dispersed, cannot appropriately control the release rate during the release period.
• Accordingly, an object of the present invention is to provide a microsphere capable of appropriately controlling the initial release amount of a biologically active substance and its release rate during a subsequent release period, and continuously releasing the biologically active substance in vivo for a predetermined period of time.
Solution to the Problem
• The present inventors earnestly studied to solve the above problem. As a result of that, the present inventors have surprisingly found that a microsphere having no mass of the biologically active substance or no empty hole of 1.5 μm or more, can appropriately control the initial release amount of a biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time. Namely, the present inventions are as follows.
• [1] The first embodiment of the present invention is a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component, in which a biologically active substance is uniformly dispersed, wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present in the microsphere.
• [2] The second embodiment of the present invention is the microsphere according to [1], wherein a mass of the biologically active substance or an empty hole of 1.0 μm or more is not present in the microsphere.
• [3] The third embodiment of the present invention is the microsphere according to [1] or [2], wherein an average volume-based particle diameter of the dispersed biologically active substance is 5 nm to 500 nm.
• [4] The fourth embodiment of the present invention is the microsphere according to any one of [1] to [3], wherein the biologically active substance is a lipophilic biologically active substance.
• [5] The fifth embodiment of the present invention is a sustained release formulation comprising the microsphere according to any one of [1] to [4].
Advantageous Effects of the Invention
• The microsphere of the present invention can appropriately control the initial release amount of a biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time.
BRIEF DESCRIPTION OF THE DRAWINGS
• FIG. 1 shows a microphotograph of leuplin (registered trademark).
• FIG. 2 shows an SEM image of a cross section of a particle of about 35 μm of leuplin (registered trademark).
• FIG. 3 shows an SEM image of a cross section of the microsphere without a biologically active substance of Reference Example 1.
• FIG. 4 shows an SEM image of a cross section of the microsphere of Example 1.
• FIG. 5 shows an SEM image of a cross section of the microsphere of Comparative Example 2.
• FIG. 6 shows an SEM image of a cross section of the microsphere of Comparative Example 3.
DESCRIPTION OF THE INVENTION
• 1. Microsphere
• The microsphere of the present invention is a microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component, in which a biologically active substance is uniformly dispersed, wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less, and a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present in the microsphere. The microsphere of the present invention can appropriately control the initial release amount of the biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time. Further, in the phrase “a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present in the microsphere”, the term “mass” means a coarse particle or an aggregate of particles of the biologically active substance, the term “empty hole” means a cavity such as an air bubble or a groove, and the term “1.5 μm or more” means that a maximum diameter is 1.5 μm or more wherein it is a maximum diameter in case of a substantially circular shape, it is a long side length in case of a rectangular shape, and it is a maximum diameter in case of a needle shape.
• <Observation of Cross Section of Microsphere>
• Absence of a mass of the biologically active substance or an empty hole of 1.5 μm or more in the microsphere, can be confirmed by observing a cross section of the microsphere with an electron microscope photograph at a magnification, for example, at which the dispersed microparticles of the biologically active substance can be confirmed. Specifically, the microsphere is first frozen with liquid nitrogen. After frozen, a cross section of FIB (focused ion beam) is prepared. That is, by using an FIB apparatus, a focused ion beam is irradiated onto a sample, and a structure at a desired position inside the sample is cut out, whereby a cross section of the microsphere is observed. A preferable particle diameter of the dispersed microparticles of the biologically active substance is several tens nm to several hundreds nm. An entire cross section of the microsphere is observed at an observation magnification of an electron microscope capable of confirming the dispersed microparticles of the above preferable particle diameter. Usually, an observation magnification of an electron microscope is from 2,500 to several tens of thousands or more. In addition, in the case where a higher magnification at which the entire microsphere cannot be observed is used, the observed portions may be joined to observe the entire microsphere. Depending on the constituent element of the biologically active substance, an elementary analysis may be performed by analyzing the cross section of the microsphere using an EDS (Energy Dispersive X-ray Spectrometer).
• <PLGA>
• PLGA is a lactic acid-glycolic acid copolymer having a constitutional unit derived from lactic acid and a constitutional unit derived from glycolic acid. PLGA may comprise another biodegradable polymer such as polylactide (PLA), polyglycolide (PGA) and the like. The PLGA described herein is described as an example, and the present invention is not limited to the described PLGA.
• The molar ratio (L:G) of the constitutional unit (L) derived from lactic acid and the constitutional unit (G) derived from glycolic acid in PLGA is not particularly limited, and may be appropriately selected according to the intended purpose. A preferable molar ratio (L:G) is 1:99 to 99:1, more preferably 25:75 to 99:1, further preferably 30:70 to 90:10, particularly preferably 50:50 to 85:15.
• PLGA used in the microsphere of the present invention can be produced, for example, by heating and condensation polymerization of lactic acid and glycolic acid under a weakly reduced pressure using an ion exchange resin as a catalyst. In this case, lactide may be used in place of lactic acid. PLGA may be a commercially available product. A commercially available product may be purchased from, for example, FUJIFILM Wako Pure Chemical Corporation, Taki Chemical Co., Ltd., Evonic Rohm GmbH, Merck KGaA, Sigma-Aldrich Co., LLC, and the like.
• The content of PLGA in the microsphere of the present invention is not particularly limited, and may be appropriately selected according to the intended purpose. The content is preferably 1% by mass or more, more preferably 30% by mass or more and 95% by mass or less, and particularly preferably 50% by mass or more and 90% by mass or less.
• <Microsphere>
• The microsphere of the present invention includes PLGA and a biologically active substance. The microsphere may further contain a dispersing agent and another component, if necessary. The biologically active substance, a dispersing agent, another component and the like are dispersed in the matrix of the microsphere.
• [Biologically Active Substance]
• A biologically active substance contained in the microsphere of the present invention is not particularly limited, and may be appropriately selected according to the intended purpose. The biologically active substance may be, for example, a pharmaceutical compound, a functional food compound, a functional cosmetic compound, and the like. A microsphere containing a pharmaceutical compound can be suitably used, for example, as a sustained release pharmaceutical formulation. The biologically active substance includes both a lipophilic biologically active substance and a hydrophilic biologically active substance. A preferable biologically active substance includes a lipophilic biologically active substance. A lipophilic biologically active substance means, for example, a substance having a log P value of water/octanol distribution coefficient of 3 or more, and a biologically active substance not contained in a lipophilic biologically active substance is classified as a hydrophilic biologically active substance. The water/octanol distribution coefficient can be measured according to the Japanese Industrial Standard: JIS Z 7260-107 (2000): Flask shaking method. The biologically active substance is not particularly limited as long as a sustained release formulation comprising the biologically active substance is desired, and may be appropriately selected according to the intended purpose. The biologically active substance includes any form of a salt, hydrate, and the like.
• A mass of the biologically active substance or an empty hole of 1.5 μm or more, preferably a mass of the biologically active substance or an empty hole of 1.0 μm or more is not present in the microsphere of the present invention. By adopting such constitution, the microsphere can appropriately control the initial release amount of the biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time. Absence of a mass of the biologically active substance or an empty hole of 1.5 μm or more, or 1.0 μm or more, can be controlled by the content of the biologically active substance, relative to the total amount of the microsphere. A preferable content of the biologically active substance varies depending on the biologically active substance, and is, for example, 0.01 to 2% by mass, preferably 0.1 to 1.5% by mass, more preferably 0.2 to 1.2% by mass, relative to the total amount of the microsphere.
• The average volume-based particle diameter of the dispersed microparticles of the biologically active substance is preferably 5 nm to 500 nm, more preferably 10 nm to 400 nm, and further preferably 20 nm to 200 nm.
• [Dispersing Agent]
• A dispersing agent may be used for dispersing the biologically active substance. The dispersing agent may be a low molecular weight dispersing agent or a high molecular weight polymer dispersing agent. A low molecular weight dispersing agent means a compound having a mass average molecular weight less than 15,000. A high molecular weight polymer dispersing agent means a compound having a mass average molecular weight of 15,000 or more, including repeated covalent bonds between one or more of monomers.
• The low molecular weight dispersing agent is not particularly limited as long as it is acceptable for a pharmaceutical compound, a functional food compound, a functional cosmetic compound, and the like, and may be appropriately selected according to the intended purpose. A specific example thereof includes a lipid, a saccharide, a cyclodextrin, an amino acid, an organic acid, another component, and the like. These may be used alone or in combination of two kinds or more thereof.
• The lipid is not particularly limited, and may be appropriately selected according to the intended purpose. The lipid may be, for example, a medium chain or long chain monoglyceride, diglyceride or triglyceride, a phospholipid, a vegetable oil (e.g. soybean oil, avocado oil, squalene oil, sesame oil, olive oil, corn oil, rape-seed oil, safflower oil, sunflower oil, etc.), a fish oil, a flavoring oil, a water-insoluble vitamin, a fatty acid, and a mixture thereof, a derivative thereof and the like. These may be used alone or in combination of two kinds or more thereof.
• The sugar is not particularly limited, and may be appropriately selected according to the intended purpose. The sugar includes, for example, glucose, mannose, idose, galactose, fucose, ribose, xylose, lactose, sucrose, maltose, trehalose, turanose, raffinose, maltotriose, acarbose, water-soluble cellulose, synthetic cellulose, sugar alcohol, glycerin, sorbitol, lactitol, maltitol, mannitol, xylitol, erythritol, polyol, and a derivative thereof, and the like. These may be used alone or in combination of two kinds or more thereof.
• The another component is not particularly limited and may be appropriately selected according to the intended purpose. The another component is preferably one which can be used for a medicine so far.
• <Average Volume-Based Particle Diameter>
• The average volume-based particle diameter of the microsphere of the present invention is 1 μm or more and 150 μm or less, preferably 10 μm or more and 100 μm or less, and more preferably 20 μm or more and 75 μm or less. The average volume-based particle diameter may be measured using a laser diffraction particle size distribution measuring apparatus. In the present invention, when the average volume-based particle diameter exceeds 150 μm, the problem of an initial burst occurs due to non-uniform dispersibility of the biologically active substance in the microsphere, which tends to cause aggregation and sedimentation, and to lead to difficult processing in a subsequent step. When the average volume-based particle diameter is smaller than 1 μm, the problem of an initial burst occurs remarkably.
• The microsphere of the present invention can appropriately control the initial release amount of a biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time.
• 2. Sustained Release Formulation
• By using the microsphere of the present invention, a sustained release formulation containing the microsphere can be prepared. The sustained release formulation of the present invention can appropriately control the initial release amount of a biologically active substance and its release rate during a subsequent release period, and can continuously release the biologically active substance in vivo for a predetermined period of time, and a pharmacological effect can be effectively exhibited.
• The sustained release formulation of the present invention can be simply administered as an injection, an implant or a transdermal formulation, directly to a lesion such as a muscle, subcutaneous tissue, blood vessel, organ, joint cavity, tumor, or the like. It may be administered as various other formulations. For example, when preparing a sustained-release preparation of the present invention as an injection formulation, the sustained release injection formulation as an aqueous suspension may be prepared together with a dispersing agent (Tween 80, HCO 60, carboxy methylcellulose, sodium alginate, etc.), a preservative (methylparaben, propylparaben, etc.), an isotonizing agent (sodium chloride, mannitol, sorbitol, glucose, etc.) and the like. Alternatively, the sustained release injection formulation as an oil suspension may be prepared with a vegetable oil such as soybean oil, sesame oil, corn oil, and the like.
• 3. Method of Producing Microsphere
• <Step of Producing Microsphere>
• The method of producing the microsphere of the present invention includes at least the step of forming particles, and may further include the step of filtration and sterilization, the step of removing a good solvent, and other steps, if necessary.
• <Step of Forming Particles>
• In the step of forming particles, it is preferable to use a pulverizing apparatus in which pulverization is performed between a plurality of processing surfaces being capable of approaching to and separating from each other, at least one of which rotates relative to the other, which is described in JP 2009-132871 or JP 2011-189348. The step of forming particles is performed, for example, by continuously feeding to the pulverizing apparatus a solution of PLGA and a biologically active substance obtained by dissolving or dispersing PLGA and the biologically active substance in a good solvent of PLGA, and a solution containing a poor solvent of PLGA to prepare emulsified particles; and removing the good solvent from the produced particles to precipitate the microsphere of the present invention. Here, “dispersing” includes dispersing the biologically active substance as a solid in a good solvent of PLGA; emulsifying the biologically active substance in a good solvent of PLGA; forming a w/o emulsion containing an aqueous solution of a hydrophilic biologically active substance and a good solvent of PLGA; and the like.
• The solution of PLGA and a biologically active substance is not particularly limited as long as it is a solution in which PLGA and the biologically active substance are dissolved or dispersed in a good solvent of PLGA, and may be appropriately selected according to the intended purpose. The good solvent is not particularly limited, and may be appropriately selected according to the intended purpose. The good solvent includes, for example, a halogenated aliphatic hydrocarbon, an aliphatic ester, an alcohol, a ketone, an ether, acetonitrile, and the like. An example of the halogenated aliphatic hydrocarbon includes dichloromethane, chloroform, carbon tetrachloride, chloroethane, 2,2,2-trichloroethane, and the like. An example of the aliphatic ester includes ethyl acetate, propyl acetate, butyl acetate, and the like. An example of the alcohol includes an alcohol having low solubility in water such as benzyl alcohol, phenyl alcohol, n-butanol, and the like. An example of the ketone includes a ketone having 3 to 6 carbon atoms (e.g., acetone, methyl ethyl ketone, methyl isobutyl ketone, cyclohexanone, etc.), and the like. An example of the ether includes an ether having 2 to 6 carbon atoms (e.g., dimethyl ether, methyl ethyl ether, diethyl ether, etc.), and the like. It is preferable to select a solvent having low solubility in water, from the view point of the content of the biologically active substance and for the purpose of preventing an initial burst. A good solvent is preferably a halogenated aliphatic hydrocarbon, a ketone, and a mixture thereof, more preferably dichloromethane, acetone and a mixture thereof. These may be used alone or in combination of two kinds or more thereof. The particle diameter can be controlled by changing a kind of the solvent or a mixing amount of the solvent.
• A good solvent means a solvent having high solubility of PLGA, and a poor solvent means a solvent having low or no solubility of PLGA. A good solvent and a poor solvent are selected so that a mass of the biologically active substance or an empty hole of 1.5 μm or more is not generated in a cross section of each microsphere. In addition, a good solvent and a poor solvent can be defined by, for example, a quantity of PLGA which can be dissolved in 100 g of the solvent at 25° C. In the present invention, the good solvent is preferably a solvent which dissolves 0.1 g or more, more preferably 0.2 g or more, and still more preferably 0.5 g or more of PLGA. The poor solvent is preferably a solvent which dissolves only 0.05 g or less, more preferably 0.02 g or less, and still more preferably 0.01 g or less of PLGA. The poor solvent is not particularly limited, and may be appropriately selected according to the intended purpose, and water is preferable.
• A content of PLGA in a solution of PLGA and a biologically active substance may be changed depending on the good solvent, depending on the particle diameter of the intended microsphere, so that a mass of the biologically active substance or an empty hole of 1.5 μm or more is not generated in a cross section of the microsphere. The content of PLGA is, for example, 1 to 30% by mass, preferably 3 to 20% by mass, and more preferably 5 to 15% by mass. The content of the biologically active substance in the PLGA solution may be appropriately changed according to the intended purpose, the pharmacological effect and the like, so that a mass of the biologically active substance or an empty hole of 1.5 μm or more is not generated in a cross section of the microsphere.
• A stabilizer may be added to the poor solvent for further ensuring stability of the produced microsphere. The stabilizer is not particularly limited, and may be appropriately selected according to the intended purpose. The stabilizer includes, for example, polyvinyl alcohol (PVA), polyvinyl pyrrolidone (PVP), carboxy methylcellulose (CMC), hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), lecithin, Polysorbate 80, and the like, and polyvinyl alcohol (PVA) is preferable. Further, the concentration of the added stabilizer is preferably 0.01 to 20% by mass, more preferably 5% by mass or less. The preferable poor solvent is, for example, an aqueous solution of PVA, and the like.
• The solution of PLGA and a biologically active substance and the solution of a poor solvent is desirably prepared using a preparation apparatus such as a rotatory dispersing apparatus which realizes uniform mixing by applying a shearing force to a fluid, for example, by rotating a stirring bar of various shapes such as a rod, a plate and a propeller in a tank, or by equipping with a screen rotating relative to a stirring bar. A stirring apparatus disclosed in JP 5147091 may be applied as a preferable example of the rotatory dispersing apparatus. It is necessary to thoroughly mix the PLGA solution and the poor solvent, for not generating a mass of the biologically active substance or an empty hole of 1.5 μm or more in a cross section of the microsphere. For complete mixing, it is necessary to aim at homogenization at least on a molecular level.
• The rotatory dispersing apparatus may be a batch type one or a continuous type one. When performed by a continuous type rotatory dispersing apparatus, a stirring energy can be appropriately controlled, by using an apparatus to continuously supply and discharge a fluid to and from the stirring tank, or using a continuous mixer without using a stirring tank, or using a known stirring apparatus or a stirring means. Incidentally, the stirring energy is described in detail in JP H04-114725 by the present applicant. The stirring method in the present invention is not particularly limited, but may be performed using a various shearing type, friction type, high-pressure jet type, ultrasonic type, etc, of a stirrer, a dissolver, an emulsifier, a disperser, a homogenizer, or the like. An example thereof includes a continuous type emulsifier such as ULTRA-TURRAX (IKA-Werke GmbH & Co. KG), POLYTRON (Kinematica AG), TK HOMOMIXER (Primix Corporation), Ebara Milder (Ebara Corporation), TK HOMOMETIC LINE FLOW (Primix Corporation), Colloid Mill (Kobelko Eco-Solutions, Co., Ltd.), Slasher (NIPPON COKE & ENGINEERING, Co., Ltd.), Trigonal Wet Pulverizer (Mitsui Miike Chemical Engineering Machinery, Co., Ltd.), Cavitron (Euro Tech, Co., Ltd.), Fine Flow Mill (Pacific Machinery & Engineering, Co., Ltd.), and the like; a batch type or continuous dual type emulsifier such as Clearmix (M. Technique Co., Ltd.), Clearmix Dissolver (M. Technique Co., Ltd.), and the like. Further, it is desirable to use a stirring apparatus equipped with a stirring blade rotating at high speed and equipped with a screen outside of the stirring blade which discharges a fluid as a jet stream from an opening of the screen, particularly, the above Clearmix (M. Technique Co., Ltd.) and Clearmix Dissolver (M. Technique Co., Ltd.).
• In the above pulverizing apparatus, it is possible to control the particle diameter and the particle diameter distribution of PLGA particles by adjusting the contact pressure of the rotating processing surfaces at a standstill period. As a result of experiments by the present inventors, the contact pressure is preferably 20 g/cm²to 250 g/cm². When the contact pressure is lower than 20 g/cm², the thin film is not stable and the particle diameter distribution becomes wide. When the contact pressure is higher than 250 g/cm², it has been found difficult to adjust the intended particle diameter. The contact pressure may be preferably 50 g/cm²to 200 g/cm², and more preferably 80 g/cm²to 150 g/cm².
• It is preferable to prevent coalescence of the respective microspheres formed by contacting the solution of PLGA and the biologically active substance with the solution containing the poor solvent. As a method of preventing the coalescence, the solution containing a poor solvent is preferably added in a tank for recovering a solution discharged fluid beforehand, and is slowly stirred. By stirring, the coalescence of the microspheres can be further suppressed. A rotatory dispersing apparatus is preferable for stirring, and Clearmix Dissolver (M. Technique Co., Ltd.) is desirable. The rotatory dispersing apparatus is not particularly limited as long as the whole solution can be made to flow mildly. When stirring is strong, the PLGA emulsified particles may break down, the distribution width may become wider, and the dispersion state of the biologically active substance may collapse.
• When a biologically active substance is a lipophilic biologically active substance, the step of forming particles can be suitably performed according to the above description, and a microsphere can be manufactured. When a biologically active substance is a hydrophilic biologically active substance, the hydrophilic biologically active substance is dispersed in a good solvent of PLGA using, for example, a dispersing agent, whereby the step of forming particles can be similarly performed to produce a microsphere.
• In addition, when a biologically active substance is a hydrophilic biologically active substance, the hydrophilic biologically active substance is dissolved in an aqueous solvent such as water together with a stabilizer, if necessary, and is mixed with a solution in which PLGA is dissolved in a good solvent of PLGA, to prepare a w/o emulsion; and the above step of forming particles is performed using the w/o emulsion as a solution of PLGA and the biologically active substance, and using the above pulverizing apparatus. For preparing the w/o emulsion, an intermittent shaking method, a propeller type stirring apparatus, a method by a mixer using a turbine type stirring apparatus, a colloid mill method, a homogenizer method, and an ultrasonic irradiation method can be used. Using the above pulverizing apparatus, this w/o emulsion of the solution of PLGA and a physiologically active substance, and a solution containing a poor solvent of PLGA are continuously added to prepare emulsified particles as a w/o/w emulsion; and the good solvent is removed from the produced particles to precipitate the microsphere of the present invention. This obtained microsphere may be used as it is, but it is also possible to further add an excipient (mannitol, sorbitol, lactose, glucose, etc.), redisperse the mixture, and freeze dry or spray dry the mixture, to be solidified. A more stable sustained release injection formulation can be obtained, by adding distilled water for injection or an appropriate dispersion medium to this solidified microsphere when used.
• <Step of Filtration and Sterilization>
• Sterile filtration of the prepared solution containing PLGA and a biologically active substance agent and the solution of a poor solvent is preferably performed prior to the step pf forming particles, if desired. The solution containing a poor solvent can be sterilized by filtration using a hydrophilic filter, and the solution of PLGA and a biologically active substance can be sterilized by filtration using a hydrophobic filter. A bore diameter of the filters used for filtration is preferably 0.1 μm to 0.45 μm, more preferably 0.2 μm.
• The above filter for sterile filtration is not particularly limited, and may be appropriately selected according to the intended purpose. For example, for sterile filtration of the solution containing a poor solvent, a hydrophilic filter such as polyvinylidene fluoride (PVDF) and polyethersulfone may be used. For sterile filtration of the solution of PLGA and a biologically active substance, a hydrophobic filter such as polytetrafluoroethylene (PTFE) may be used. The filter for sterile filtration is not limited to the material described here, but it is necessary to be selected depending on adsorption of the medicine and a kind of the solvent.
• <Step of Removing a Good Solvent>
• In the step of removing a good solvent, a good solvent is removed from the emulsified particles containing PLGA and a biologically active substance. The step of removing a good solvent is not particularly limited, and may be appropriately selected according to the intended purpose, as long as the good solvent can be removed from the emulsified particles so that a mass of a biologically active substance or an empty hole of 1.5 μm or more is not generated in a cross section of the microsphere. The step of removing a good solvent includes, for example, a method of evaporating and removing the good solvent from the fluid, by at least one of heating the fluid with stirring, flowing a gas such as nitrogen on a surface of the fluid, and reducing a pressure of the fluid. It is preferable to remove a good solvent quickly for not generating a mass of a biologically active substance or an empty hole of 1.5 μm or more or 1.0 μm or more in the microsphere. A time of removing the good solvent may be, for example, 30 minutes to 12 hours, preferably 1 to 10 hours, and more preferably 2 to 8 hours.
• <Other Steps>
• Other steps include, for example, a solvent composition preparation, a classification step, a particle cleaning step, and the like. Normally, coarse powder cut or fine powder cut is performed in the classification step, but the particles produced in the present invention do not substantially need the classification step. However, a classification step may be included just in case.
• By the above production method, it is possible to produce a microsphere having no mass of a biologically active substance or no empty hole of 1.5 μm or more in a cross section of the microsphere.
EXAMPLE
• Hereinafter, the present invention is explained in more detail with reference to Examples, but the present invention is not limited only to these Examples.
Reference Example 1
• In Reference Example 1, microspheres (PLGA microparticles) without a biologically active substance were prepared. Using the microspheres of Reference Example 1 as an index, cross sections of the microspheres of Examples and Comparative Examples were observed as SEM images, and the dispersion states of the biologically active substance in the microspheres of Examples and Comparative Examples were confirmed below.
• <Preparation of PLGA Solution and Aqueous PVA Solution>
• Dichloromethane (Kanto Chemical Co., Inc.) was added to lactic acid-glycolic acid copolymer (Resomer RG504, Evonik AG) so that the concentration was 13% by mass. Lactic acid-glycolic acid copolymer was dissolved using a high-speed rotatory dispersing apparatus Clearmix Dissolver (M. Technique Co., Ltd.) to obtain PLGA solution. Thereafter, the solution was filtrated with a 0.2 μm vent filter (φ 62, Merck KGaA). Ion exchanged water was added to polyvinyl alcohol (PVA, EG-40P, Nippon Synthetic Chemical Industry Co., Ltd.) so that the concentration was 1.5% by mass, and polyvinyl alcohol was dissolved using a high-speed rotatory dispersing apparatus Clearmix (M. Technique Co., Ltd.) to obtain an aqueous PVA solution. Thereafter, the solution was filtrated with a hydrophilic PVDF membrane filter (φ 47, Merck KGaA). The aqueous PVA solution was added in a tank for collecting PLGA emulsified particles beforehand, and was slowly stirred to an extent that the solution surface just moved.
• <Preparation of Microsphere (PLGA Microparticles)>
• As the step of forming particles, the prepared PLGA solution and the aqueous PVA solution were mixed using the pulverizing apparatus described in JP 2011-189348. Here, the pulverizing apparatus described in JP 2011-189348 is an apparatus described inFIG. 25 of the publication, in which the opening of the second part d20 has a concentric annular shape which is surrounding the central opening of theprocessing surface2 which is a ring-shaped disc, and a disk diameter is 75 mm. Specifically, the prepared aqueous PVA solution was introduced from the first introduction path d1 into the space between the processing surfaces1 and2 at 0.02 MPaG, at 65 mL/min and at 30° C., and the prepared PLGA solution was introduced from the second introduction path d2 into the space between the processing surfaces1 and2 at 0.65 MPaG, at 20 mL/min and at 30° C. at the rotational speed of the processing member10 of 2,000 rpm, and the aqueous PVA solution and the PLGA solution were mixed in a forced thin film to prepare PLGA emulsified particles containing dichloromethane into the space between the processing surfaces1 and2. The fluid containing PLGA emulsified particles (hereinafter, PLGA emulsified particle dispersion) in the space between the processing surfaces1 and2 was discharged from the space between the processing surfaces1 and2 of the pulverizing apparatus. The PLGA emulsified particle dispersion was collected in a recovery tank through an outer casing61 for collecting the discharged PLGA emulsified particle dispersion.
• Next, as the step of removing a solvent, argon gas was blown onto the fluid surface to remove dichloromethane over 3.5 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing PLGA microparticles (PLGA microparticle suspension). The average volume-based particle diameter of the obtained PLGA microparticles was 34.0 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image (FIG. 3) was observed.
• As shown inFIG. 3, it was confirmed that a biologically active substance or an empty hole was not present in the FIB section. Further, it was found that the cross section of the microsphere of Reference Example 1 could be used as an index in observation of cross sections of the microspheres of Examples and Comparative examples.
Example 1
• <Preparation of Solution of PLGA and Biologically Active Substance and Aqueous PVA Solution>
• Dichloromethane (Kanto Chemical Co., Inc.) was added to lactic acid-glycolic acid copolymer (Resomer RG504, Evonik AG) and progesterone (FUJIFILM Wako Pure Chemical Corporation, for cell biochemistry) as a biologically active substance, so that the concentration of lactic acid-glycolic acid copolymer was 13% by mass, and the concentration of progesterone was 1.0% by mass. Lactic acid-glycolic acid copolymer and progesterone were dissolved using a high-speed rotatory dispersing apparatus Clearmix Dissolver (M. Technique Co., Ltd.) to obtain a solution of PLGA and the biologically active substance. Thereafter, the solution was filtrated with a 0.2 μm air vent filter (φ 62, Merck KGaA). An aqueous PVA solution was prepared in the same manner as in Reference Example 1. The aqueous PVA solution was added in a tank for collecting emulsified particles of PLGA and the biologically active substance beforehand, and was slowly stirred to an extent that the solution surface just moved.
• <Preparation of Microsphere>
• As the step of forming particles, the prepared solution of PLGA and the biologically active substance and the aqueous PVA solution were mixed using the pulverizing apparatus described in JP 2011-189348 in the same manner as in Reference Example 1. Specifically, the prepared aqueous PVA solution was introduced from the first introduction path d1 into the space between the processing surfaces1 and2 at 0.02 MPaG, at 65 mL/min and at 30° C., and the prepared solution of PLGA and the biologically active substance was introduced from the second introduction path d2 into the space between the processing surfaces1 and2 at 0.65 MPaG, at 20 mL/min of 30° C. at the rotational speed of the processing member10 of 2,000 rpm, and the aqueous PVA solution and the solution of PLGA and the biologically active substance were mixed in a forced thin film to prepare emulsified particles of PLGA and the biologically active substance containing dichloromethane in the space between the processing surfaces1 and2. The fluid containing the emulsified particles of PLGA and the biologically active substance (hereinafter, emulsified particle dispersion of PLGA and the biologically active substance) in the space between the processing surfaces1 and2 was discharged from the space between the processing surfaces1 and2 of the pulverizing apparatus. The emulsified particle dispersion of PLGA and the biologically active substance was collected in a recovery tank through an outer casing61 for collecting the discharged emulsified particle dispersion of PLGA and the biologically active substance.
• Next, as the step of removing a solvent, argon gas was blown on the fluid surface to remove dichloromethane over 3.5 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing microspheres (microsphere suspension). The average volume-based particle diameter of the obtained microspheres was 35.5 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image (FIG. 4) was observed.
• As shown inFIG. 4, it was confirmed that a mass of the biologically active substance or an empty hole of 1.5 μm or more was not present in the FIB section. It was confirmed that the biologically active substance was uniformly dispersed as microparticles of 0.1 μm to 0.22 μm in the microsphere.
Example 2
• As the step of forming particles, an emulsified particle dispersion of PLGA and the biologically active substance was prepared in the same manner as in Example 1. Next, as the step of removing a solvent, argon gas was flown on the collected discharged fluid to remove dichloromethane over 8 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing microspheres (microsphere suspension). The average volume-based particle diameter of the obtained microspheres was 35.3 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image was observed.
• From observation of the SEM image, it was confirmed that a mass of the biologically active substance or an empty hole of 1.5 μm or more was not present in the FIB section. It was confirmed that the biologically active substance was uniformly dispersed as microparticles of 0.1 μm to 0.55 μm in the microsphere.
Comparative Example 1
• As the step of forming particles, an emulsified particle dispersion of PLGA and the biologically active substance was prepared in the same manner as in Example 1. Next, as the step of removing a solvent, dichloromethane was removed in the atmosphere from the collected discharged fluid over 15 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing microspheres (microsphere suspension). The average volume-based particle diameter of the obtained microspheres was 35.4 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image was observed.
• From observation of the SEM image, masses of the biologically active substance of 1.5 μm or more were confirmed in the FIB section. It was confirmed that the biologically active substance was ununiformly dispersed as microparticles of 0.1 μm to 1.7 μm in the microsphere.
Example 3
• Dichloromethane (Kanto Chemical Co., Inc.) was added to lactic acid-glycolic acid copolymer (Resomer RG504, Evonik AG) and progesterone (FUJIFILM Wako Pure Chemical Corporation, for cell biochemistry) as a biologically active substance, so that the concentration of lactic acid-glycolic acid copolymer was 13% by mass, and the concentration of progesterone was 0.75% by mass. Lactic acid-glycolic acid copolymer and progesterone were dissolved using a high-speed rotatory dispersing apparatus Clearmix Dissolver (M. Technique Co., Ltd.) to obtain a solution of PLGA and the biologically active substance. Thereafter, the solution was filtrated with a 0.2 μm air vent filter (φ 62, Merck KGaA). An aqueous PVA solution was prepared in the same manner as in Reference Example 1. The aqueous PVA solution was added in a tank for collecting emulsified particles of PLGA and the biologically active substance beforehand, and was slowly stirred to an extent that the solution surface just moved.
• <Preparation of Microsphere>
• As the step of forming particles, the prepared solution of PLGA and the biologically active substance and the aqueous PVA solution were mixed using the pulverizing apparatus described in JP 2011-189348 in the same manner as in Reference Example 1. Specifically, the prepared aqueous PVA solution was introduced from the first introduction path d1 into the space between the processing surfaces1 and2 at 0.025 MPaG, at 50 mL/min and at 30° C., and the prepared solution of PLGA and the biologically active substance was introduced from the second introduction path d2 into the space between the processing surfaces1 and2 at 0.6 MPaG, at 16 mL/min of 30° C. at the rotational speed of the processing member10 of 1,800 rpm, and the aqueous PVA solution and the solution of PLGA and the biologically active substance were mixed in a forced thin film to prepare emulsified particles of PLGA and the biologically active substance containing dichloromethane in the space between the processing surfaces1 and2. The fluid containing the emulsified particles of PLGA and the biologically active substance (hereinafter, emulsified particle dispersion of PLGA and the biologically active substance) in the space between the processing surfaces1 and2 was discharged from the space between the processing surfaces1 and2 of the pulverizing apparatus. The emulsified particle dispersion of PLGA and the biologically active substance was collected in a recovery tank through an outer casing61 for collecting the discharged emulsified particle dispersion of PLGA and the biologically active substance.
• Next, as the step of removing a solvent, argon gas was blown on the fluid surface to remove dichloromethane over 2.0 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing microspheres (microsphere suspension). The average volume-based particle diameter of the obtained microspheres was 28.5 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image was observed.
• From observation of the SEM image, it was confirmed that a mass of the biologically active substance or an empty hole of 1.5 μm or more was not present in the FIB section. It was confirmed that the biologically active substance was uniformly dispersed as microparticles of 0.3 μm to 0.7 μm in the microsphere.
Example 4
• Dichloromethane (Kanto Chemical Co., Inc.) was added to lactic acid-glycolic acid copolymer (Resomer RG504, Evonik AG) and progesterone (FUJIFILM Wako Pure Chemical Corporation, for cell biochemistry) as a biologically active substance, so that the concentration of lactic acid-glycolic acid copolymer was 13% by mass, and the concentration of progesterone was 1.0% by mass. Lactic acid-glycolic acid copolymer and progesterone were dissolved using a high-speed rotatory dispersing apparatus Clearmix Dissolver (M. Technique Co., Ltd.) to obtain a solution of PLGA and the biologically active substance. Thereafter, the solution was filtrated with a 0.2 μm air vent filter (φ 62, Merck KGaA). Thereafter, a microsphere suspension was obtained in the same manner as in Example 3. The average volume-based particle diameter of the obtained microspheres was 28.8 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image was observed.
• From observation of the SEM image, it was confirmed that a mass of the biologically active substance or an empty hole of 1.5 μm or more was not present in the FIB section. It was confirmed that the biologically active substance was uniformly dispersed as microparticles of 0.3 μm to 0.9 μm in the microsphere.
Comparative Example 2
• Dichloromethane (Kanto Chemical Co., Inc.) was added to lactic acid-glycolic acid copolymer (Resomer RG504, Evonik AG) and progesterone (FUJIFILM Wako Pure Chemical Corporation, for cell biochemistry) as a biologically active substance, so that the concentration of lactic acid-glycolic acid copolymer was 13% by mass, and the concentration of progesterone was 2.0% by mass. Lactic acid-glycolic acid copolymer and progesterone were dissolved using a high-speed rotatory dispersing apparatus Clearmix Dissolver (M. Technique Co., Ltd.) to obtain a solution of PLGA and the biologically active substance. Thereafter, the solution was filtrated with a 0.2 μm air vent filter (φ 62, Merck KGaA). An aqueous PVA solution was prepared in the same manner as in Reference Example 1. The aqueous PVA solution was added in a tank for collecting emulsified particles of PLGA and the biologically active substance beforehand, and was slowly stirred to an extent that the solution surface just moved.
• <Preparation of Microsphere>
• As the step of forming particles, the prepared solution of PLGA and the biologically active substance and the aqueous PVA solution were mixed using the pulverizing apparatus described in JP 2011-189348 in the same manner as in Reference Example 1. Specifically, the prepared aqueous PVA solution was introduced from the first introduction path d1 into the space between the processing surfaces1 and2 at 0.025 MPaG, at 50 mL/min and at 30° C., and the prepared solution of PLGA and the biologically active substance was introduced from the second introduction path d2 into the space between the processing surfaces1 and2 at 0.6 MPaG, at 16 mL/min of 30° C. at the rotational speed of the processing member10 of 1,800 rpm, and the aqueous PVA solution and the solution of PLGA and the biologically active substance were mixed in a forced thin film to prepare emulsified particles of PLGA and the biologically active substance containing dichloromethane in the space between the processing surfaces1 and2. The fluid containing the emulsified particles of PLGA and the biologically active substance (hereinafter, emulsified particle dispersion of PLGA and the biologically active substance) in the space between the processing surfaces1 and2 was discharged from the space between the processing surfaces1 and2 of the pulverizing apparatus. The emulsified particle dispersion of PLGA and the biologically active substance was collected in a recovery tank through an outer casing61 for collecting the discharged emulsified particle dispersion of PLGA and the biologically active substance.
• Next, as the step of removing a solvent, argon gas was blown on the fluid surface to remove dichloromethane over 2.0 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing microspheres (microsphere suspension). The average volume-based particle diameter of the obtained microspheres was 28.9 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image (FIG. 5) was observed.
• As shown inFIG. 5, masses of the biologically active substance of 1.5 μm or more were confirmed in the FIB section. It was confirmed that the biologically active substance was ununiformly dispersed as microparticles of 0.1 μm to 1.6 μm in the microsphere.
Comparative Example 3
• As the step of forming particles, an emulsified particle dispersion of PLGA and the biologically active substance was collected in a recovery tank in the same manner as in Example 4. Next, as the step of removing a solvent, dichloromethane was removed in the atmosphere from the collected discharged fluid over 36 hours, while stirring the discharged fluid at a peripheral speed of 4.7 m/sec using Clearmix Dissolver (M. Technique Co., Ltd.), to obtain a suspension containing microspheres (microsphere suspension). The average volume-based particle diameter of the obtained microspheres was 28.6 μm. Representative particles were frozen with liquid nitrogen, and an FIB cross section was prepared, and an SEM image (FIG. 6) was observed.
• As shown inFIG. 6, masses of the biologically active substance of 1.5 μm or more were confirmed in the FIB section. It was confirmed that the biologically active substance was ununiformly dispersed as microparticles of 2.0 μm to 4.3 μm in the microsphere, and in particular, a large amount of the biologically active substance was present in the surface layer (the outermost shell part of the microsphere).
• A part of the preparation conditions of the microspheres of Examples 1 to 4 and Comparative Examples 1 to 3, and the particle diameters of the prepared microspheres are shown in Tables 1 and 2.

• 	TABLE 1
  			Comparative
  	Example 1	Example 2	Example 1

  Concentration of	13%	by mass	13%	by mass	13%	by mass
  PLGA
  Concentration of	1.0%	by mass	1.0%	by mass	1.0%	by mass
  progesterone

  Drying condition	Argon blowing	Argon flow	In atmosphere
  	3.5 hours	8 hours	15 hours

  Particle diameter of	35.5	μm	35.3	μm	35.4	μm
  microsphere

  Particle diameter of	0.1 to 0.22 μm	0.1 to 0.55 μm	0.1 to 1.7 μm
  biologically acitve
  substance

• As can be seen from Table 1, the particle diameters of the microparticles of the biologically active substance varied according to the drying condition and the drying time in Examples 1 and 2 and Comparative Example 1. In other words, the particle diameter of the microparticles of the biologically active substance in Example 1 was 0.1 to 0.22 μm, which was dried for 3.5 hours under the condition of argon blowing. The particle diameter in Example 2, increased to 0.1 to 0.55 μm, which was dried for 8 hours under the condition of argon flow. The particle diameter in Comparative Example 1 was as large as 0.1 to 1.7 μm, and some of the particle diameter exceeded 1.5 μm, which was dried for 15 hours under the atmospheric condition. Thus, by controlling the drying condition and the drying time, the microsphere of the present invention in which a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present, can be produced.

• 	TABLE 2
  			Comparative	Comparative
  	Example 3	Example 4	Example 2	Example 3

  Concentration of	13%	by mass	13%	by mass	13%	by mass	13%	by mass
  PLGA
  Concentration of	0.75%	by mass	1.0%	by mass	2.0%	by mass	1.0%	by mass
  probucol

  Drying condition	Argon blowing	Argon blowing	Argon blowing	In atmosphere
  	2.0 hours	2.0 hours	2.0 hours	36 hours

  Particle diameter of	28.5	μm	28.8	μm	28.9	μm	28.6	μm
  microsphere

  Particle diameter of	0.3 to 0.7 μm	0.3 to 0.9 μm	0.1 to 1.6 μm	2.0 to 4.3 μm
  biologically acitve
  substance

• As can be seen in Table 2, the particle diameters of the microparticles of the biologically active substance varied according to the content of the biologically active substance in Examples 3 and 4 and Comparative Example 2. In other words, the particle diameter of the microparticles of the biologically active substance in Example 3 was 0.3 to 0.7 μm, in which the content was 0.75% by mass. The particle diameter in Example 4, increased to 0.3 to 0.9 μm, in which the content was 1.0% by mass. Further, the particle diameter in Comparative Example 2, increased to 0.1 to 1.6 μm, and some of the particle diameter exceeded 1.5 μm, in which the content was 2.0% by mass. In addition, the particle diameter in Comparative Example 3, increased to 2.0 to 4.3 μm, and some of the particle diameter exceeded 1.5 μm, which was dried for 36 hours under the atmospheric condition. Thus, by controlling the content of the biologically active substance, the microsphere of the present invention in which a mass of the biologically active substance or an empty hole of 1.5 μm or more is not present, can be produced.
INDUSTRIAL APPLICABILITY
• The present invention provides a microsphere capable of appropriately controlling the initial release amount of a biologically active substance and its release rate during a subsequent release period, and continuously releasing the biologically active substance in vivo for a predetermined period of time.

Claims (8)

1. A microsphere comprising a lactic acid-glycolic acid copolymer (PLGA) as a main component,

wherein an average volume-based particle diameter of the microsphere is 1 μm or more and 150 μm or less,

a biologically active substance is uniformly dispersed inside the microsphere, and

a mass of the biologically active substance or an empty hole of 1.5 μm or more is not observed inside the microsphere, in an electron microscope image of a cross section of the microsphere.

2. The microsphere according toclaim 1, wherein a mass of the biologically active substance or an empty hole of 1.0 μm or more is not observed inside the microsphere.

3. The microsphere according toclaim 1, wherein an average volume-based particle diameter of the dispersed biologically active substance is 5 nm to 500 nm.

4. The microsphere according toclaim 1, wherein the biologically active substance is a lipophilic biologically active substance.

5. A sustained release formulation comprising the microsphere according toclaim 1.

6. A sustained release formulation comprising the microsphere according toclaim 2.

7. A sustained release formulation comprising the microsphere according toclaim 3.

8. A sustained release formulation comprising the microsphere according toclaim 4.

Images